These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Agonists of luteinizing hormone-releasing hormone in prostate cancer. Rick FG; Block NL; Schally AV Expert Opin Pharmacother; 2013 Nov; 14(16):2237-47. PubMed ID: 23984804 [TBL] [Abstract][Full Text] [Related]
65. Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH. Schally AV; Wang H; He J; Cai R; Sha W; Popovics P; Perez R; Vidaurre I; Zhang X Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12028-12033. PubMed ID: 30373845 [TBL] [Abstract][Full Text] [Related]
66. Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice. Kahán Z; Varga JL; Schally AV; Rékási Z; Armatis P; Chatzistamou L; Czömpöly T; Halmos G Breast Cancer Res Treat; 2000 Mar; 60(1):71-9. PubMed ID: 10845811 [TBL] [Abstract][Full Text] [Related]
67. The effect of GHRH antagonists on human glioblastomas and their mechanism of action. Pozsgai E; Schally AV; Zarandi M; Varga JL; Vidaurre I; Bellyei S Int J Cancer; 2010 Nov; 127(10):2313-22. PubMed ID: 20162575 [TBL] [Abstract][Full Text] [Related]
68. Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone. Pinski J; Schally AV; Groot K; Halmos G; Szepeshazi K; Zarandi M; Armatis P J Natl Cancer Inst; 1995 Dec; 87(23):1787-94. PubMed ID: 7473836 [TBL] [Abstract][Full Text] [Related]
69. Growth-inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice. Dondi D; Moretti RM; Montagnani Marelli M; Pratesi G; Polizzi D; Milani M; Motta M; Limonta P Int J Cancer; 1998 May; 76(4):506-11. PubMed ID: 9590126 [TBL] [Abstract][Full Text] [Related]
70. Antagonists of growth hormone-releasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells. Siejka A; Schally AV; Block NL; Barabutis N Prostate; 2010 Jul; 70(10):1087-93. PubMed ID: 20232355 [TBL] [Abstract][Full Text] [Related]
71. Inhibition of experimental small-cell and non-small-cell lung cancers by novel antagonists of growth hormone-releasing hormone. Wang H; Zhang X; Vidaurre I; Cai R; Sha W; Schally AV Int J Cancer; 2018 Jun; 142(11):2394-2404. PubMed ID: 29435973 [TBL] [Abstract][Full Text] [Related]
72. Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Csernus VJ; Schally AV; Kiaris H; Armatis P Proc Natl Acad Sci U S A; 1999 Mar; 96(6):3098-103. PubMed ID: 10077643 [TBL] [Abstract][Full Text] [Related]
73. Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers. Plonowski A; Schally AV; Busto R; Krupa M; Varga JL; Halmos G Peptides; 2002 Jun; 23(6):1127-33. PubMed ID: 12126741 [TBL] [Abstract][Full Text] [Related]
74. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice. Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally AV Cancer; 1994 Feb; 73(4):1229-38. PubMed ID: 8313327 [TBL] [Abstract][Full Text] [Related]
75. Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function. Szalontay L; Schally AV; Popovics P; Vidaurre I; Krishan A; Zarandi M; Cai RZ; Klukovits A; Block NL; Rick FG Cell Cycle; 2014; 13(17):2790-7. PubMed ID: 25486366 [TBL] [Abstract][Full Text] [Related]
76. Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix. Rozsa B; Nadji M; Schally AV; Dezso B; Flasko T; Toth G; Mile M; Block NL; Halmos G Prostate; 2011 Apr; 71(5):445-52. PubMed ID: 20859992 [TBL] [Abstract][Full Text] [Related]
77. Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. Buchholz S; Schally AV; Engel JB; Hohla F; Heinrich E; Koester F; Varga JL; Halmos G Proc Natl Acad Sci U S A; 2007 Feb; 104(6):1943-6. PubMed ID: 17261802 [TBL] [Abstract][Full Text] [Related]
78. Increase in amphiregulin and epiregulin in prostate cancer xenograft after androgen deprivation-impact of specific HER1 inhibition. Tørring N; Hansen FD; Sørensen BS; Ørntoft TF; Nexø E Prostate; 2005 Jun; 64(1):1-8. PubMed ID: 15651060 [TBL] [Abstract][Full Text] [Related]
79. Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling. Kanashiro CA; Schally AV; Zarandi M; Hammann BD; Varga JL Int J Cancer; 2004 Nov; 112(4):570-6. PubMed ID: 15382037 [TBL] [Abstract][Full Text] [Related]
80. Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer. Rick FG; Schally AV Urol Oncol; 2015 Jun; 33(6):270-4. PubMed ID: 25512159 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]